Virstatin is a versatile bioactive molecule that targets various biological processes and pathogens. In the context of Vibrio cholerae O395deltalacZ, it inhibits ToxT-mediated transcriptional activation of multiple promoters (tcpA, acfD, ctxAB, tagA, tcpI, acfA, aldA) with an average inhibitory activity ranging from 3.0% to 15.0% at a concentration of 100 µM. Additionally, Virstatin shows inhibition of sodium fluorescein uptake in OATP1B3 and OATP1B1-transfected CHO cells, with inhibition rates of 112.71% and 113.05% at 10 µM, respectively, indicating potential as an OATP1B3 and OATP1B1 transporter inhibitor.
The compound also exhibits a broad spectrum of bioactivities, including the inhibition of Menin-MLL interactions in leukemia, Chronic Active B-Cell Receptor Signaling, ELG1-dependent DNA repair, malarial parasite plastid, HP1-beta Chromodomain interactions, and Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1). It also demonstrates synthetic lethality in tumor cells producing 2HG and inhibits MBNL1-poly(CUG) RNA binding.
In the context of antiviral activity, Virstatin has shown to inhibit cytotoxicity induced by SARS-CoV-2 in various cell lines, such as Caco-2 and VERO-6 cells, at a concentration of 10 µM. It also inhibits the SARS-CoV-2 3CL-Pro protease at 20 µM with an inhibition rate of 11.36%, and has shown activity against the SARS-CoV-2 (USA-WA1/2020 strain) in HRCE cells.
Furthermore, Virstatin demonstrates inhibitory effects against human HDAC6, although with relatively low inhibition percentages of -3.55% and -1.41% using different peptide substrates. Overall, the compound displays a diverse range of bioactivities with potential therapeutic implications in infectious diseases, cancer, and other conditions related to its numerous targets..
Note: Summary generated by AI. Data source: ChEMBL 